Latest:
Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer
Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Katherine Clifton, MD
Latest:
Insights From SABCS 2024 and Future Directions in Breast Cancer
Dr. Gandhi and Dr. Clifton explore clinical decision-making and sequencing for selective estrogen receptor degraders (SERDs), antibody-drug conjugates (ADCs), and other targeted therapies in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), balancing efficacy, safety, and patient characteristics, while highlighting promising data from the 2024 San Antonio Breast Cancer Symposium (SABCS) and the role of precision medicine in improving outcomes and patient experiences.
Sapna Patel, BA, MD
Sapna Patel, MD, is a professor in the Division of Medical Oncology, the leader of the Cutaneous Oncology Program, and the William Robinson Endowed Chair in Cancer Research at the University of Colorado Cancer Center.
Latest:
RP1: An Emerging Intratumoral Therapy
Panelists discuss the promising systemic responses of RP1, an oncolytic virus therapy for melanoma, emphasizing its expanded applicability through visceral tumor injection and the need for further data to optimize dosing strategies and confirm durability compared with other treatments.
Hadeel Assad, MD
Hadeel Assad, MD, is an associate professor, clinician educator, and medical oncologist at Wayne State University and Karmanos Cancer Institute
Latest:
The Move From Blood to Solid: Open Opportunities for CAR T-Cell Therapy in Solid Tumors
There remains a significant unmet need for better treatments that prolong life and preserve the quality of life in women with metastatic breast cancer.
Josh Ruess, MD
Latest:
Closing Perspectives: Unmet Needs, Emerging Advances, and the Future of Early-Stage NSCLC Treatment
Panelists discuss how future advances will focus on biomarker-driven personalized approaches, platform trials to increase pathologic complete response rates, circulating tumor DNA (ctDNA)-guided therapy escalation and de-escalation, and the critical importance of comprehensive molecular testing in the neoadjuvant setting.
Tisch Cancer Institute
Latest:
Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients
Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.
Jin-Ji Yang, MD
Jin-Ji Yang, MD is an oncologist at Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, at the Guangdong Academy of Medical Sciences at the Southern Medical University.
Latest:
Dr Yang on Osimertinib Plus Savolitinib in MET-Aberrant, EGFR-Mutant Advanced NSCLC
Jin-Ji Yang, MD, discusses osimertinib plus savolitinib as a first-line treatment in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC.
John Crown, BCh, BAO, BSc, MD, MBA
Latest:
Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast Cancer
John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.
Susan E. Waltz, PhD
Latest:
Women in Oncology: Self-Advocacy in a Busy Field
Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.